[1] |
CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing.
Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
|
[2] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[3] |
LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan.
One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822.
|
[4] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[5] |
YANG Jingqi, XU Baohai, ZHANG Jing, JIANG Yang, SHI Fang.
Pharmacovigilance for Traditional Chinese Patent Medicines for Orthopedics
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 436-441.
|
[6] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[7] |
SUN Ximu, ZHOU Han, LI Yanming, GUO Peng, NIE Xiaolu.
Signal Mining and Analysis of ICIs-Associated Thrombocytopenia Adverse Events Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 23-28.
|
[8] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[9] |
SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng.
Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
|
[10] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[11] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[12] |
SHAO Bo, GUO Xiaoxin.
Review of pharmacovigilance of traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 741-745.
|
[13] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[14] |
LIU Yadi, ZHANG Xiaomeng, CAI Haili, CHEN Siying, WANG Yu, ZHANG Bing.
Traditional Chinese medicine for prevention and treatment of adriamycin cardiotoxicity and an empirical study of evidence elements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 759-764.
|
[15] |
CAI Haili, ZHANG Xiaomeng, LIU Yadi, LIU Shujia, GAO Fujun, WANG Yu, ZHANG Bing.
Progress in construction and evaluation of a drug-induced cardiotoxicity model
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 765-770.
|